European Innovation Worldwide

China Mission Shanghai May 27th-31st 2013 Delegation Brochure

ERAIEnterprise

Rhône-Alpes International

(France)

BIOM

Biotech Cluster Development

(Germany)

BIOPMEDPiemonte

Innovation Cluster(Italy)

LYONBIOPOLERhone-Alpes Biocluster

(France)

BIOCATBioRegion of

Catalonia(Spain)

www.lyonbiopole.com

www.erai.org

www.bio-m.org

www.biopmed.eu

www.biocat.cat

The bioXclusters regions bring together more than 1700 companies

developing their activity mainly in the fields of oncology, personali-

sed medicine, cardiovascular, neurological, infectious, inflam-

matory and autoimmune diseases. Each region also brings its own

specialties to the consortium.

Our companies work with innovative approaches in cutting-edge

scientific research projects, maintaining a dynamic environment for

facing the current market and patients’ needs.

The project focus will be on the USA, Brazil and China, with the aim

of expanding to other partner countries in the long run.

bioXclusters is the biotechnology and human health project that

off ers you the opportunity of establishing partnerships with a wide

network of SMEs in Europe!

Companies

1 700

YOUR PARTNER IN EUROPE FORBIOTECH AND HUMAN HEALTH!

bioXclusters is a project supported by the European Union that

unites four leading biotechnology and health care clusters with

the objective of fostering the internationalisation of the wide and

innovative network of Small and Medium Enterprises (SMEs) in the

participating regions.

Bavaria (Germany), Catalonia (Spain), Piedmont (Italy) and Rhône-Al-

pes (France) join their knowledge, skills, best practices and dyna-

mic companies in life sciences, with a focus on drug development,

healthcare and medical technology. Together, we are a strong and

multifaceted partner for other regions of the world.

The project also benefits from the know-how and the long-standing

experience of the ERAI agency (Entreprise Rhône-Alpes International),

who is the key enforcer of the Rhône-Alpes region for its international

economic development.

Number of employeesin private sector

103 000

Number of scientistsin public research

14 000

Numberof clinical trials

3 600

Am Klopferspitz 19 a82152 Martinsried - Germany www.bio-m.org

BioM is the coordinating agency of the Bavarian & Munich Biotech Clusters, and the network hub for all biotechnology companies and start-ups in the region, one of the top biotech hotspots in Europe. BioM is government-fun-ded and provides services to biotech SMEs, including marketing, BD, consulting, training, trade missions, and an information portal at www.bio-m.org. A recent focus area is the “m4 Initiative for Personalized Medicine”, a large industry-academia collaboration program.

Dr. Daniela Tonn - International Affairs & Trainingtonn@bio-m.org

Cfm Oskar Tropitzsch e.K. Waldershofer Str. 49-51, 95615 Marktredwitz, Germanywww.cfmot.de

Assistance to the pharmaceutical and biotechnological industry in sourcing and producing chemical specialties. We supply the product which our custo-mer is looking for, with the right documentation, the correct quantity from mg to mt and proper quality, to support projects from RnD state up to commercial production. To achieve these goals we use our excellent knowhow and world-wide network of qualified suppliers.

Mr. Oskar Tropitzsch - CEOinfo@cfmot.de

Germany Trade and Invest (GTAI) GmbH“Health-Made in Germany”Friedrichstraße 60, 10117 Berlin, Germanywww.gtai.de

GTAI is the economic development agency of the Federal Republic of Germany and the coordinator of the “Health – Made in Germany” programme, an initiative of the

Iris Biotech GmbHWaldershofer Str. 49-51, 95615 Marktredwitz, Germanywww.iris-biotech.de

Specialized in reagents for Drug Discovery, Drug Delivery and Diagnostics. Our specific expertises are special amino acids and unusual building blocks for peptide synthesis and peptide mimetics. We provide unique and sophis-ticated polymers for Polymer Therapeutics. We have specific know-how and production capabilities to supply products, from grams to bulk quantities.

Dr. Thomas Bruckdorfer - CSOinfo@iris-biotech.de

Passeig de Gràcia 103. 3rd Floor08008 Barcelona – Spainwww.biocat.cat

Biocat is the organization that promotes life sciences in Catalonia through the implementation of specific programs and initiatives, facilitating access to financing and talent, and internationalization. It is fostered by the Gover-nment of Catalonia, the City Council, companies, hospitals and research institutions. Catalonia bioregion is made of 520 companies, 54 research institutes, 20 science & technology parks, 15 hospitals with research acti-vity and 12 universities with studies in life sciences, that altogether have in operation more than 400 research groups working on life sciences.

Dr. Montserrat Vendrell – CEOmvendrell@biocat.catMamen Martí – Head of Internationalisationcmarti@biocat.catB

IOX

CLU

STE

RS

PAR

TN

ER

SC

OM

PAN

IES ARCHIVEL Farma

Fogars de Tordera, 61. Polígon Industrial Bonavista08916 BADALONA - SPAINwww.archivelfarma.com

Biopharmaceutical company specialized in the development of new agents for preventing and treating tuberculosis and other diseases susceptible to immunomodulatory interventions. In collaboration with the “Institute for Research in Health Sciences Germans Trias i Pujol”, it has developed “RUTI®”, a novel adjunctive immunotherapy and therapeutic vaccine for the treatment of tuberculosis. After having completed a phase II clinical trial it is ready to start a phase III clinical trial to prove efficacy.

Olga Rue Claros – CEOorue@archivelfarma.comLuis Ruiz Avila - VP Business Developmentlruiz@janusdevelopments.com

EnantiaBaldiri Reixac 1008028 Barcelona - Spainwww.enantia.com

Enantia is a company devoted to chemical research and process develo-pment, custom synthesis and crystal engineering, with a strong focus on asymmetric chemistry and co-crystallization technologies.Our mission is to provide fully integrated chemistry services for the fine chemical, pharmaceutical and biotech sectors. We can contribute all the way from initial research in medicinal chemistry or route scouting to any phase of the chemical process R&D.

Joan Feixas - CEOjfeixas@enantia.comLlorenç Rafecas – Technical Directorlrafecas@enantia.com

Via Ribes 510010 Collerettto Giacosa (To) – Italywww.biopmed.eu

bioPmed is the Italian innovation cluster dedicated to health care created in 2009 thanks to the intervention of Piemonte Region in the framework of ERDF - POR Piemonte 2007-2013 - Innovation clusters action. bioPmed is based on a community of around 390 companies and different universities and research centres involving more of 3900 scientists, foundations and associations active in Life Sciences fields. The initiative is led by Bioindustry Park Silvano Fumero (www.bioindustrypark.eu), the local science & technology park.

Fabrizio Conicella – Director Business Development and International Projects bioPmed cluster coordinatorconicella@bioindustrypark.it

Genovax SrlVia Ribes 5 10010 Colleretto Giacosa (TO) – ITALYwww.genovax.it

Development of vaccines for chronic diseases, aiming at re-establishing the original physiological profile of the immune system. 2 projects under development:

•GX101aimstodemonstratethepossibilitytore-establishtheimmu nological tolerance in patients affected by lupus, by means of a tolerogenic vaccination. •GX301aimstoevaluateefficacyandtolerabilityoftelomerasepeptides as a therapeutic approach in patients affected by advanced renal and prostate cancer.

Domenico Criscuolo - Presidentdcriscuolo@genovax.it

Verum.de GmbHSembdnerstrasse 5, 82110 Germering, Germanywww.verum.de

Verum has been the first Western-Standard CRO specializing in CEE/CIS coun-tries, key competence is full clinical service for Phase II-IV. Verum has successfully completed more than 130 Clinical Trials with about 40,000 patients for pharma, biotech and medical device companies as well as the US NIH. The company’s expertise covers cardiovascular, neurology, psychiatry, CNS, pain, oncology, and more. Operating since 1992, Verum is the strongest player in high recruiting CEE areas and maintains offices all over Eastern Europe, Germany and the US.

Dr. Dagmar Siebold - Director Client Relationsds@verum.de

MorphoSys AGLena-Christ-Str. 48, 82152 Martinsried, Germanywww.morphosys.com

MorphoSys developed HuCAL, the most successful human antibody library in the pharmaceutical industry. With Ylanthia, the company recently launched the next generation antibody technology. By applying its proprietary technologies, MorphoSys has become a leader in the field of therapeutic antibodies. Together with its partners, MorphoSys has built a pipeline of more than 70 antibody drug candidates. MorphoSys is also developing proprietary therapeutic antibody candidates in the area of inflammation and oncology.

Dr. Peter Ruile - Senior Director Business Developmentbd@morphosys.com

German Federal Ministry for Economy and Technology. It supports export activities of the German health care industry by connecting existing trade promoting measures, offe-ring political support as well as organizing specific marketing activities in target markets.

Ms. Marion Luekemann - Senior Managerinfo@exportinitiative-gesundheitswirtschaft.de

ZAC Confluence. 8 rue Montrochet.69285 Lyon Cedex Francewww.erai.com

ERAI (Entreprise Rhône-Alpes International) is the agency for the internatio-nal economic development of the Rhône-Alpes region. ERAI is an internatio-nal network of 27 off� ices in 21 countries. It is mobilised to act in Rhône-Alpes and abroad to provide assistance to companies and clusters from the region in their international development, and to guide foreign companies to set up their business in Rhône-Alpes.

For more than 20 years, ERAI has been assisting more than 5,000 companies from Rhône-Alpes in various industries, technologies and niches to develop their international presence.

Elisabetta Schena - International Cluster Development Project Manager elisabetta.schena@erai.orgKanny Ly - Project Director kanny.ly@erai.cn

Bâtiment Domilyon321 avenue Jean Jaurès, 69007 Lyon - Francewww.lyonbiopole.com

Accredited as a world competitiveness cluster in 2005, Lyonbiopole is focused on the fight against human and animal infectious diseases and cancers. Centre of excellence in vaccines and diagnostics, it aims to strengthen the competitiveness of Rhône-Alpes health companies. Designed as an interface tool between public and private research, it implements actions to foster collaborative R&D, to support projects and to increase strategic and financial partnerships for companies’ econo-mic and international development. It also provides access to shared facilities and platforms.

Isabelle Scarabin - Economic & International Aff airs Director isabelle.scarabin@lyonbiopole.com

ADOCIA115 avenue Lacassagne69003 Lyon - Francewww.adocia.com

Adocia is specialized in the development of “Best-In-Class” medicines with already approved therapeutic proteins. Its mission is to off er innovative treatments. In this purpose, our company has developed a protein delivery platform, BioChaperone®, for the formulation of proteins in order to improve their eff icacy and stability. This technology has been applied to 3 classes of proteins: Hormones (BioChaperone Human Insulin) Growth Factors and Monoclonal Antibodies.

Remi Soula - Business Development Directorr.soula@adocia.com

Fab’entechImmeuble Domilyon, 321 Avenue Jean Jaurès 69007 Lyon - Francewww.fabentech.com

Founded in 2009 Fab’entech is a biopharmaceutical company which deve-lops and commercializes innovative passive immunotherapeutic solutions based on specific polyclonal immunoglobulins [F(ab’)2] in emerging infec-tious diseasesIn a context of emerging infectious diseases (Avian flu H5N1, CCHF, Ebola, Nipah, Lassa and SARS), it develops flexible custom specific polyclonal immunoglobulins responding where there is no satisfactory therapeutic solution.

Bertrand Lepine - CEO & Founderbertrand.lepine@fabentech.com

MetabolysFaculté de Médecine Laennec69372 Lyon Cedex 08 - Francewww.metabolys.com

Metabolys acts as a CRO to predict early during the preclinical develop-ment the safety and eff icacy of drug candidates/chemicals/biologics using cellular metabolomics, an innovative approach. Cellular metabolomics provides panoramic view both of the metabolic pathways in any human or animal cell type in vitro and the beneficial and adverse eff ects of milligram amounts of test compounds with these metabolic pathways. It has also a drug discovery line in the diabetes.

Gabriel Baverel - CEObaverel@sante.univ-lyon1.fr

CTI-Biotech5 avenue Lionel Terray 69330 Meyzieu - Francewww.ctibiotech.com

CTI-BIOTECH studies adult and neonatal stem cell populations to investi-gate biological systems regulating cell proliferation and diff erentiation. It validates technologies enabling 2D and 3-dimensional tissue engineering. CTI-BIOTECH runs pre-clinical and clinical programs to enable cell therapy applications and 3D bioassays for molecular screening and toxicology platforms from human stem cells.

Colin McGuckin - Directorc.mcguckin@ctibiotech.comNico Forraz – Directornico.forraz@ctibiotech.com

Coordinated by:

Partners:

This initiative is supported by the European Commission’s Directorate-General for Enterprise and Industry and financed under the Competitiveness and Innovation Framework Programme (CIP).

“EU Initiative Promoting SME Internationalisation Through Clusters”